Antibody Drug Conjugate Market Size, Share, Trends And Growth Analysis, Industry Forecast To 2025

Antibody Drug Conjugate Market Size, Share, Trends And Growth Analysis, Industry Forecast To 2025

ID: 1530856
recent pressrelease next pressrelease

(businesspress24) - According to the latest report published by Credence Research, Inc.
Market Insights
Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs such as chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers with liable bonds. They combine the unique targeting property of monoclonal antibodies with the cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased tissues. Currently marketed drugs suffers from various stipulations like low potency, lack of specificity and adverse effects. This has forced the pharmaceutical and research companies to develop therapeutics that can overcome these barriers. Commercializing antibody drug conjugates have overcome these scenarios and improve the medical conditions. The currently marketed antibody drug conjugate drugs are Adcetris (Seattle Genetics) and Kadcyla (Genentech/Roche) followed by several Antibody Drug Conjugates (ADCs) in pipeline showcase the potential for innovations in this market.
Browse the full report Antibody Drug Conjugate Market: Market Growth, Future Prospects and Competitive Analysis, 2016-2024 at http://www.credenceresearch.com/report/antibody-drug-conjugate-market
In base year 2015, North America accounted for the largest market in the antibody drug conjugate market due to the presence of major pharmaceutical companies working on the development of antibody drug conjugate drugs. Moreover, one of the prime reason of North Americais manufactured by the Europe based pharmaceutical giant, Roche. Additionally, Europe was the second region after where the commercialization of the ADCs were approved on a fast-track basis. Asia pacific is anticipated to be the fastest growing segment in the antibody drug conjugate market due to the approval of ADCs in Japan, China.
Market Competition Assessment:
The antibody drug conjugate market currently possesses only two companies having their drugs marketed. However, many companies have their molecules in the clinical development stage which hit market during the forecast period. The companies include Immunomedics, Spirogen, Pfizer, Roche/Genentech, Oxford BioTherapeutics, and Others.


Browse the full report Antibody Drug Conjugate Market: Market Growth, Future Prospects and Competitive Analysis, 2016-2024 at http://www.credenceresearch.com/report/antibody-drug-conjugate-market
Key Market Movements:

https://www.credenceresearch.com/report/purging-compounds-market
https://www.credenceresearch.com/report/air-management-systems-market
https://www.credenceresearch.com/report/ocular-drug-delivery-technologies-market
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we
Media Contact
Name: Chris Smith
Designation: Global Sales Manager
Ph: 1-800-361-8290
Email: sales(at)credenceresearch.com
Web: http://www.credenceresearch.com/



More information:
http://https://www.credenceresearch.com/report/antibody-drug-conjugate-market



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:

8003618290



published by: satyamspot
print pressrelease  send to a friend  

Date: 12/26/2017 - 05:50
Language: English
News-ID 1530856
Character count: 4544
Kontakt-Informationen:
Firma: Credence Research
Ansprechpartner: jayvir singh Feedback to businesspress24.com about Pressrelease-id:
Stadt: San Jose
Telefon: 8003618290

Meldungsart: Erfolgsprojekt
Versandart: Veröffentlichung
Freigabedatum: 26.12.2017
Comments:



Number of hits: 834

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 374
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 32


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.